Screener
Viking Therapeutics VKTX Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Revenues | Three Months Ended March 31, 2026 / — | Three Months Ended March 31, 2025 / — |
|---|---|---|
| Operating expenses: | ||
| Research and development | 150,150 | 41,391 |
| General and administrative | 13,975 | 14,078 |
| Total operating expenses | 164,125 | 55,469 |
| Loss from operations | (164,125) | (55,469) |
| Other income (expense): | ||
| Amortization of financing costs | — | (24) |
| Interest income, net | 5,800 | 9,864 |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's total operating expenses?
- Viking Therapeutics (VKTX) reported total operating expenses of $164.13M in Q1 2026.
- How has Viking Therapeutics's total operating expenses changed year-over-year?
- Viking Therapeutics's total operating expenses increased by 195.9% year-over-year, from $55.47M to $164.13M.
- What is the long-term trend for Viking Therapeutics's total operating expenses?
- Over 4 years (2021 to 2025), Viking Therapeutics's total operating expenses has grown at a 63.0% compound annual growth rate (CAGR), from $55.68M to $393.34M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Viking Therapeutics's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude